Cardiol's Phase II pericarditis data published in JAHA as Phase III MAVERIC nears full enrollment

Cardiol Therapeutics Inc. announced on July 14, 2026 that results from its Phase II MAvERIC study were published in the Journal of the American Heart Association. The company said the publication reports the Phase II MAvERIC study results in JAHA.¹ This release timing coincides with the pivotal Phase III MAVERIC trial approaching full patient enrollment.¹

According to the publication, CardiolRx was linked to fast and lasting decreases in pericarditis pain and inflammation among patients with a high baseline disease burden, along with sizable drops in the number of pericarditis episodes per year and a favorable safety and tolerability profile.¹ The company said these Phase II findings form the basis for the ongoing Phase III trial, which it described as a randomized, double-blind, placebo-controlled study testing whether CardiolRx can lower the risk of pericarditis coming back.¹

CEO David Elsley said the JAHA publication makes the complete set of peer-reviewed Phase II data available to the wider cardiovascular field.¹ He added that the Phase II results shaped the design of the Phase III MAVERIC study.¹

The MAVERIC program consists of two studies: a completed Phase II trial known as MAvERIC-Pilot (NCT05494788) and an ongoing pivotal Phase III trial (NCT06708299).¹ Separately, the FDA has given CardiolRx Orphan Drug Designation for pericarditis, including the recurrent form of the disease.¹

The company also disclosed that it is developing another product, CRD-38, a subcutaneously administered formulation aimed at inflammatory heart disease including heart failure.¹